Polyethylene

Bormed™ LE6600-PH

We confirm that this product fulfils the requirements on materials used for the manufacturing of articles or components of articles intended for medical use as described in:

Council of Europe Material complies with the following European Pharmacopoeia monographs:

Monograph 3.1.3. Polyolefins

Monograph 3.1.4. Polyethylene without additives for containers for parenteral

preparations and for ophthalmic preparations

Tests are made according to the current Pharmacopoeia edition at the time of the

testing: 10th edition (2020), and supplement 10.5 (07/2021).

Monograph 3.2.2. Plastic containers and closures for pharmaceutical use: This monograph relates specifically to the <u>container and closure system</u> and does not contain tests that are required for compliance assessment of the raw materials used for said container and closures. The composition of the product is in

compliance with this monograph.

Germany The product follows the VDI 2017 Guideline on "Medical Grade Plastic" that

covers the requirements for change management, quality management, supply

security and support for regulatory requirements.

USA Material has passed the following United States Pharmacopeia tests:

Biological reactivity tests - in vitro <87>: Cytotoxicity (Elution test)

Biological reactivity tests - in vivo <88>: Class VI - 70 °C

Physicochemical tests for plastics according to <661>, so far applicable to polymer pellets (with no reference to the specific surface area requirements), including heavy metals, buffering capacity and non-volatile residue test with

purified water, alcohol and hexane extracts.

Plastic materials of construction <661.1>: Identification, physicochemical and

extractable metals (as listed in the chapter) tests.

Tests are made according to the current Pharmacopeia edition at the time of the

testing (USP 36/41/2021).

Elemental impurities During the manufacturing process of this product, we neither use nor intentionally

incorporate any Class 1, 2A, 2B or 3 elements as listed in the ICH Q3D(R2)

Guideline on Elemental Impurities (May 2022).

DMF number Material has been assigned the FDA Drug Master File number(s):

DMF 027587

or modification of Bormed grades, such pre-notice period needs to be included in

Technical Delivery Specifications.

This edition of the document supersedes any previous editions.

Borealis reserves the right to modify this document at any time, so please ensure to view it frequently. Changes to this document may be made with or without notice. Please always ensure that you are viewing the latest edition by

downloading documents directly from our website at www.borealisgroup.com.

Prepared by Borealis, Group Product Stewardship

Bormed is a trademark of the Borealis group.





STATEMENT ON COMPLIANCE TO REGULATIONS ON MEDICAL USE

Polyethylene

Bormed LE6600-PH

Disclaimer

The product(s) mentioned herein are not intended for use as medical implant material or implantable medical devices and we do not support their use for such applications.

To the best of our knowledge, the information contained herein is accurate and reliable as of the date of publication; however we do not assume any liability whatsoever for the accuracy and completeness of such information.

Borealis makes no warranties which extend beyond the description contained herein. Nothing herein shall constitute any warranty of merchantability or fitness for a particular purpose.

It is the customer's responsibility to inspect and test our products in order to satisfy itself as to the suitability of the products for the customer's particular purpose. The customer is responsible for the appropriate, safe and legal use, processing and handling of our products.

No liability can be accepted in respect of the use of Borealis' products in conjunction with other materials. The information contained herein relates exclusively to our products when not used in conjunction with any third party materials.

